AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33575989
Drug: Intravenous Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Methylprednisolone (IVMP) 30 mg/kg/d for 3 days followed by oral prednisolone taper
Trial: 35175308
Drug: Intravenous Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Methylprednisolone (IVMP)
Trial: 33575989
Drug: Oral Prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Prednisolone (OP) 4 mg/kg/d for two weeks followed by taper
Trial: 33575989
Drug: Oral Prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Prednisolone (OP)
Trial: 36029412
Drug: ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 3 mg/kg (ipi3)
Trial: 36029412
Drug: high-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose interferon (HDI)
Trial: 33512814
Drug: Interscalene brachial
RxNorm normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene brachial plexus block with 20 mL 0.5% bupivacaine
Trial: 33512814
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia using Ranawat cocktail (60 mL applied to subacromial space and glenohumeral joint)
Trial: 33909203
Drug: Lapatinib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib + capecitabine (L + C)
Trial: 33051083
Drug: Lowest postoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lowest postoperative haemoglobin concentration <110 g L−1
Trial: 33051083
Drug: Postoperative haemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative haemoglobin concentrations <88 g L−1
Trial: 33051083
Drug: Postoperative haemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative haemoglobin concentrations >113 g L−1
Trial: 33051083
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with lowest postoperative haemoglobin concentration >110 g L−1
Trial: 34368943
Drug: Sublingual (SL)
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual (SL) 50 mg ketamine lozenge
Trial: 34368943
Drug: Oral (PO)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (PO) 50 mg ketamine lozenge
Trial: 34368943
Drug: SL placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SL placebo lozenge
Trial: 34368943
Drug: PO placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO placebo lozenge
Trial: 35993480
Drug: Sildenafil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (50 mg)
Trial: 33470329
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (TAPT) - aspirin, ticagrelor, and tirofiban
Trial: 32896775
Drug: Lurasidone 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 160 mg/day
Trial: 34129720
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of dopamine during donor management
Trial: 34129720
Drug: Tidal volumes
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tidal volumes ≤8 ml/kg predicted body weight
Trial: 32544575
Drug: Hypofractionated radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated radiation therapy (HFRT)
Trial: 32113878
Drug: Dinoprostone 3
RxNorm normalized name: dinoprostone 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone 3 mg vaginally
Trial: 34786651
Drug: Finerenone 10
RxNorm normalized name: finerenone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone 10 or 20 mg once daily, titrated based on serum potassium and estimated glomerular filtration rate.
Trial: 34786651
Drug: Finerenone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone (10 to 20 mg)
Trial: 33239108
Drug: 10 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg/kg/min landiolol infusion
Trial: 33239108
Drug: Termination of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Termination of landiolol infusion
Trial: 33239108
Drug: Pharmacokinetics of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetics of landiolol
Trial: 32703038
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg policosanol + 20 mg atorvastatin (group D)
Trial: 35643280
Drug: OIT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OIT with placebo antihistamines
Trial: 35643280
Drug: OIT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OIT with antihistamines
Trial: 35329390
Drug: Physiotherapy program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy program to train strength and coordination of the masticatory muscles, details on dosage and duration not available.
Trial: 37804430
Drug: Midazolam 2
RxNorm normalized name: midazolam 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 2 mg
Trial: 36119062
Drug: BK-SE36 (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BK-SE36 (intramuscular route)
Trial: 36119062
Drug: BK-SE36 (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BK-SE36 (subcutaneous route)
Trial: 36119062
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (Synflorix® via IM route)
Trial: 35434945
Drug: Okra whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Okra whole fruit capsules (1,000 mg) taken orally every 6 hours for 8 weeks
Trial: 35434945
Drug: Placebo capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule taken orally every 6 hours for 8 weeks
Trial: 32252101
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg/kg BM)
Trial: 36581796
Drug: Praziquantel (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (40 mg/kg)
Trial: 32362221
Drug: Modified quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified quadruple therapy (rabeprazole 20 mg bid, amoxicillin 1 g bid, metronidazole 500 mg tid, bismuth subcitrate 300 mg qid)
Trial: 32362221
Drug: Bismuth-containing quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth-containing quadruple therapy (rabeprazole 20 mg bid, bismuth subcitrate 300 mg qid, metronidazole 500 mg tid, tetracycline 500 mg qid)
Trial: 32433709
Drug: Blood cadmium
RxNorm normalized name: cadmium
DrugBank: Cadmium (DB14085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood cadmium quartile 4 (1.63-57.81 μg/L)
Trial: 32433709
Drug: Lowest blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest blood cadmium quartile (0.00-0.53 μg/L)
Trial: 32019509
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioural therapy (GCBT) plus treatment as usual (TAU)
Trial: 32019509
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list (WL) plus treatment as usual (TAU)
Trial: 35505452
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia pretreatment with lidocaine‐prilocaine cream (EMLA)
Trial: 35505452
Drug: Water‐based cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water‐based cream (placebo)
Trial: 34647992
Drug: Filgotinib 200
RxNorm normalized name: nilotinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib 200 mg once daily for 12 weeks
Trial: 32377822
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment for non-infectious uveitis
Trial: 33341062
Drug: Usual preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual preparation in auscultation learning strategies
Trial: 32171774
Drug: Levothyroxine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine (starting dose of 50 µg daily)
Trial: 36494824
Drug: Usual practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual practice (control group) with additional monthly data contribution.
Trial: 32431191
Drug: Topical tacrolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tacrolimus 0.1% ointment once a day (QD)
Trial: 37929602
Drug: Bempedoic acid
RxNorm normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bempedoic acid 180 mg daily
Trial: 38587822
Drug: Placebo (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (single dose)
Trial: 35514022
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone (maximum dose 40 mg/daily)
Trial: 33478397
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D2 supplementation (60,000 IU/week for 12 weeks)
Trial: 33478397
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin D2 supplementation (20,000 IU/week for 12 weeks)
Trial: 33478397
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D2 supplementation
Trial: 33478397
Drug: Low-dose vitamin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose vitamin D2 supplementation
Trial: 32679209
Drug: Booster injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster injection
Trial: 32417993
Drug: Sorafenib dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib dose interruption
Trial: 32417993
Drug: Sorafenib dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib dose reduction
Trial: 33742551
Drug: 0.20 mg
RxNorm normalized name: FENTANYL 10.20 mg in 1 [USP'U] TRANSDERMAL PATCH [Fentanyl]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.20 mg ranibizumab
Trial: 33742551
Drug: 0.12 mg
RxNorm normalized name: iodine 0.12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12 mg ranibizumab
Trial: 34467531
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no additional treatment)
Trial: 33675460
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum (4-mg)
Trial: 33675460
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum (2-mg)
Trial: 35345256
Drug: Control (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (routine hydration therapy)
Trial: 36190737
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral and intravenous)
Trial: 35109140
Drug: High-dose TG-DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose TG-DHA supplementation (2,040 mg DHA daily for six months)
Trial: 35991062
Drug: Daily life
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily life activities without any intervention (Control)
Trial: 37001911
Drug: Mirikizumab 600
RxNorm normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirikizumab 600 mg
Trial: 35171954
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement containing a mixture of Boswellia serrata Roxb., chlorophyll, green tea extract, glucosamine, chondroitin sulfate, hyaluronic acid, and non-hydrolised type II collagen for 60 days
Trial: 35606829
Drug: Empiric antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric antibiotics (ampicillin and gentamicin)
Trial: 35994847
Drug: Diterpene ginkgolides
RxNorm normalized name: terpene resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diterpene ginkgolides meglumine injection (DGMI)
Trial: 35217440
Drug: Tanezumab 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab 2.5 mg, subcutaneous every 8 weeks for 56 weeks
Trial: 38650049
Drug: Tanezumab 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab 2.5 mg
Trial: 32304415
Drug: 1‐deamino‐8‐D‐arginine vasopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1‐deamino‐8‐D‐arginine vasopressin (0.4 µg/kg) + platelet transfusion (2 U)
Trial: 32453198
Drug: Metronidazole as
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole as part of multimodal therapy
Trial: 32722939
Drug: O3FAs/PPs group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O3FAs/PPs group: Oral omega-3 fatty acids (O3FAs) two capsules twice daily (total daily dose of 1040 mg/day) for 6 months with punctal plugs.
Trial: 32722939
Drug: PPs group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPs group: Punctal plugs with oral placebo.
Trial: 35218145
Drug: Family-based behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based behavioural social facilitation treatment (FBSFT)
Trial: 32106777
Drug: Revefenacin 175
RxNorm normalized name: REVEFENACIN 175MCG/3ML INHL SOLN 3ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Revefenacin 175 µg
Trial: 36108881
Drug: Single-row repair
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-row repair with horizontal LHBT augmentation
Trial: 35466521
Drug: b.i.d. amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: b.i.d. amoxicillin for 7 days
Trial: 35466521
Drug: b.i.d. amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: b.i.d. amoxicillin for 10 days
Trial: 35466521
Drug: t.i.d. amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t.i.d. amoxicillin for 7 days
Trial: 35466521
Drug: t.i.d. amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t.i.d. amoxicillin for 10 days
Trial: 35081747
Drug: Atezolizumab +
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab + Bevacizumab prior to or in combination with TACE
Trial: 33798298
Drug: Jin's three-needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jin's three-needle therapy and motor relearning regimen
Trial: 32735782
Drug: Cannabidiol 400
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol 400 mg
Trial: 39069154
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (control)
Trial: 32737054
Drug: dDAVP oral
RxNorm normalized name: DDAVP Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dDAVP oral lyophilisate administered sublingually as a single dose after a water load.
Trial: 32737054
Drug: dDAVP oral
RxNorm normalized name: DDAVP Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dDAVP oral lyophilisate
Trial: 33947446
Drug: COVID-19 convalescent
RxNorm normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 convalescent plasma (CCP) approximately 500 mL
Trial: 33369704
Drug: Rucaparib 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib 500 mg twice daily
Trial: 38971950
Drug: Rucaparib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib 600 mg twice daily
Trial: 32925337
Drug: Ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (4 mg)
Trial: 39007997
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg caffeine
Trial: 35238144
Drug: Topical finasteride
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical finasteride
Trial: 34634163
Drug: Oral finasteride
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral finasteride
Trial: 33926704
Drug: Administration of
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of antithrombin III (n = 64)
Trial: 33926704
Drug: Non-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-administration of antithrombin III (n = 77)
Trial: 33634665
Drug: Treatment-While-Incarcerated (TWI)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-While-Incarcerated (TWI)
Trial: 32050695
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group performing daily soccer routine (CG)
Trial: 36107530
Drug: Bevel facing
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevel facing left (Group L)
Trial: 33261542
Drug: Fructose (75g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructose (75g in 200mL solution)
Trial: 32316801
Drug: Leucovorin rescue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin rescue at 24 hours after HDMTX infusion
Trial: 32316801
Drug: Leucovorin rescue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin rescue at 18 hours after HDMTX infusion
Trial: 32882429
Drug: MG probing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG probing plus post‐procedural topical sulfacetamide/prednisolone ointment (Blephamide®)
Trial: 33878763
Drug: Algorithm B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm B (high-dose algorithm considering additional insulin for fat protein units)
Trial: 32240527
Drug: Dupilumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab (300 mg every 2 weeks)
Trial: 34737296
Drug: Peg-IFN-α-2b therapy
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-IFN-α-2b therapy
Trial: 38085312
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus insulin
Trial: 34792531
Drug: Chemoradiotherapy (CRT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (CRT) before chemotherapy
Trial: 33129376
Drug: Venetoclax (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (800 mg per day orally) plus bortezomib (1·3 mg/m2) and dexamethasone (20 mg orally)
Trial: 33129376
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus bortezomib (1·3 mg/m2) and dexamethasone (20 mg orally)
Trial: 33438529
Drug: 3DIZI-guided injections
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3DIZI-guided injections
Trial: 33438529
Drug: Standard ultrasound-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ultrasound-guided injections
Trial: 32155200
Drug: Combined antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined antiretroviral therapy (cART)
Trial: 34755389
Drug: 500 ml of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml of semi‐skimmed milk containing approximately 600 mg of calcium with 200 µg of cholecalciferol
Trial: 35246030
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus dose, followed by a 2 mg/kg/h continuous infusion)
Trial: 39320582
Drug: Tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10 mg BID
Trial: 39320582
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg BID
Trial: 32362168
Drug: Dietary advice
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary advice combined with oral nutritional supplements
Trial: 36263240
Drug: Nonsurgical spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsurgical spinal decompression therapy (NSDT)
Trial: 35487526
Drug: 50.4 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50.4 Gy to the primary tumour and surrounding mesorectum with concurrent chemotherapy (capecitabine, 5-fluorouracil/leucovorin or omitted)